Should I buy or sell ALX Oncology stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALXO shares. View ALXO analyst ratings or view top-rated stocks .

What is ALX Oncology's stock price target for 2024?

7 brokerages have issued 12-month price objectives for ALX Oncology's stock. Their ALXO share price targets range from $11.00 to $27.00. On average, they anticipate the company's stock price to reach $18.83 in the next year. This suggests a possible upside of 17.1% from the stock's current price. View analysts price targets for ALXO or view top-rated stocks among Wall Street analysts .

How have ALXO shares performed in 2024?

ALX Oncology's stock was trading at $14.89 at the beginning of the year. Since then, ALXO shares have increased by 8.0% and is now trading at $16.08. View the best growth stocks for 2024 here .

Are investors shorting ALX Oncology?

ALX Oncology saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,120,000 shares, an increase of 7.2% from the March 15th total of 2,910,000 shares. Based on an average daily trading volume, of 389,200 shares, the short-interest ratio is currently 8.0 days. Currently, 11.5% of the company's stock are short sold. View ALX Oncology's Short Interest .

When is ALX Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ALXO earnings forecast .

How were ALX Oncology's earnings last quarter?

ALX Oncology Holdings Inc. (NASDAQ:ALXO) posted its quarterly earnings results on Thursday, March, 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by $0.09.

What ETF holds ALX Oncology's stock?

Inspire Small/Mid Cap ETF holds 33,156 shares of ALXO stock, representing 0.23% of its portfolio.

What other stocks do shareholders of ALX Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON) , Deere & Company (DE) , GrowGeneration (GRWG) , Innovative Industrial Properties (IIPR) , Immunomedics (IMMU) , Teck Resources (TECK) , Abbott Laboratories (ABT) , Ability (ABIL) , AbbVie (ABBV) and

When did ALX Oncology IPO?

ALX Oncology (ALXO) raised $128 million in an IPO on Friday, July 17th 2020. The company issued 8,000,000 shares at a price of $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are ALX Oncology's major shareholders?

ALX Oncology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.20%). Insiders that own company stock include Jason Lettmann , Jaume Pons , Lsv Associates, Llc, Peter S Garcia, Peter S Garcia , Shelly Pinto and Sophia Randolph . View institutional ownership trends .

How do I buy shares of ALX Oncology?

Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALXO

ALX Oncology (ALXO) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)

Free ALXO Stock Alerts

$16.08

+1.59 (+10.97%)

(As of 04/17/2024 ET)

Compare

Today's Range: $14.60
▼
$17.04
50-Day Range: $10.72
▼
$16.79
52-Week Range: $3.94
▼
$17.42

Volume: 2.03 million shs
Average Volume: 431,500 shs
Market Capitalization: $806.41 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.83

Get ALX Oncology alerts:

ALX Oncology MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 17.1% Upside
$18.83 Price Target
Short Interest: Bearish
11.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.44
Based on 12 Articles This Week
Insider Trading: Selling Shares
$223,000 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.33) to ($2.85) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.58 out of 5 stars

Medical Sector

654th out of 913 stocks

Pharmaceutical Preparations Industry

284th out of 402 stocks

2.4

Analyst's Opinion

Consensus Rating
ALX Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
ALX Oncology has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.47% of the float of ALX Oncology has been sold short.
Short Interest Ratio / Days to Cover
ALX Oncology has a short interest ratio ("days to cover") of 8.
Change versus previous month
Short interest in ALX Oncology has recently increased by 7.22%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ALX Oncology does not currently pay a dividend.
Dividend Growth
ALX Oncology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALXO.

2.5

News and Social Media Coverage

News Sentiment
ALX Oncology has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for ALX Oncology this week, compared to 2 articles on an average week.
Search Interest
7 people have searched for ALXO on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added ALX Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ALX Oncology insiders have sold 348.12% more of their company's stock than they have bought. Specifically, they have bought $49,764.00 in company stock and sold $223,000.00 in company stock.
Percentage Held by Insiders
50.30% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.97% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ALX Oncology are expected to grow in the coming year, from ($3.33) to ($2.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ALX Oncology is -4.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ALX Oncology is -4.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ALX Oncology has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About ALX Oncology Stock (NASDAQ:ALXO)

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

ALXO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALXO Stock News Headlines

April 6, 2024 | insidertrades.com

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 20,000 Shares

March 19, 2024 | insidertrades.com

ALX Oncology Holdings Inc. (NASDAQ:ALXO) CEO Jason Lettmann Acquires 4,400 Shares

April 18, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

April 17, 2024 | americanbankingnews.com

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update

April 17, 2024 | americanbankingnews.com

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from Analysts

April 14, 2024 | americanbankingnews.com

ALX Oncology (NASDAQ:ALXO) Rating Reiterated by Cantor Fitzgerald

April 13, 2024 | uk.investing.com

ALX Oncology hold rating reiterated with steady stock target by Stifel

April 11, 2024 | americanbankingnews.com

ALX Oncology (NASDAQ:ALXO) Shares Gap Up to $12.14

April 18, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

April 11, 2024 | americanbankingnews.com

ALX Oncology (NASDAQ:ALXO) Earns Buy Rating from HC Wainwright

April 11, 2024 | markets.businessinsider.com

Buy Rating on ALX Oncology Holdings Amid Strong Clinical Data and Favorable rNPV Analysis

April 9, 2024 | globenewswire.com

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

April 8, 2024 | markets.businessinsider.com

Buy Rating Justified by Promising Evorpacept Trial Results and Market Potential

April 7, 2024 | americanbankingnews.com

Jaume Pons Sells 20,000 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) Stock

April 6, 2024 | finance.yahoo.com

ALX Oncology Holdings Inc (ALXO) Insider Sells Shares

March 20, 2024 | investing.com

Alx Oncology CEO buys $49.7k in company shares

March 17, 2024 | finance.yahoo.com

ALXO Apr 2024 7.000 put

March 16, 2024 | finance.yahoo.com

ALXO Apr 2024 19.000 call

March 16, 2024 | finance.yahoo.com

ALXO Apr 2024 14.000 put

March 8, 2024 | markets.businessinsider.com

ALX Oncology’s Evorpacept Shows Promising Potential in Cancer Treatment Studies

March 8, 2024 | markets.businessinsider.com

ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer

March 8, 2024 | realmoney.thestreet.com

ALX Oncology just downgraded at Stifel, here's why

March 8, 2024 | finance.yahoo.com

ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending

March 8, 2024 | investorplace.com

ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q4 2023

March 7, 2024 | globenewswire.com

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 5, 2024 | globenewswire.com

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

February 15, 2024 | wsj.com

ALX Oncology Holdings Inc.

See More Headlines

Receive ALXO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ALXO
CUSIP: N/A
CIK: 1810182
Web: www.alxoncology.com
Phone: 650-466-7125
Fax: N/A
Employees: 72
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.83
High Stock Price Target: $27.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +14.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-160,800,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -76.10%
Return on Assets: -62.59%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 5.24
Quick Ratio: 5.24

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.81 per share
Price / Book: 4.30

Miscellaneous

Outstanding Shares: 50,150,000
Free Float: 24,925,000
Market Cap: $821.96 million
Optionable: Optionable
Beta: 1.58

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Corey S. Goodman Ph.D. (Age 72)
Executive Chairman
Comp: $84k
Mr. Jason W. Lettmann (Age 47)
CEO & Director
Comp: $60.5k
Dr. Jaume Pons Ph.D. (Age 57)
Founder, President, Director & Chief Scientific Officer
Comp: $856.29k
Mr. Peter S. Garcia M.B.A. (Age 62)
Chief Financial Officer
Comp: $631.11k
Dr. Sophia Randolph M.D. (Age 56)
Ph.D., Chief Medical Officer & Director
Comp: $637.24k
Dr. Michael Chang Ph.D.
Vice President of Operations
Ms. Shelly Pinto (Age 47)
Senior VP of Finance & Chief Accounting Officer
Comp: $508.26k
Dr. Christopher Byrd J.D.
Ph.D., General Counsel
Dr. Athanasios Tsiatis M.D.
Senior Vice President of Clinical Development
Dr. Lin Yeong-Liang M.D.
M.S., Senior Vice President of Drug Safety & Pharmacovigilance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALXO Stock Analysis - Frequently Asked Questions

Should I buy or sell ALX Oncology stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALXO shares.
View ALXO analyst ratings or view top-rated stocks.
What is ALX Oncology's stock price target for 2024?: 7 brokerages have issued 12-month price objectives for ALX Oncology's stock. Their ALXO share price targets range from $11.00 to $27.00. On average, they anticipate the company's stock price to reach $18.83 in the next year. This suggests a possible upside of 17.1% from the stock's current price.
View analysts price targets for ALXO or view top-rated stocks among Wall Street analysts.
How have ALXO shares performed in 2024?: ALX Oncology's stock was trading at $14.89 at the beginning of the year. Since then, ALXO shares have increased by 8.0% and is now trading at $16.08.
View the best growth stocks for 2024 here.
Are investors shorting ALX Oncology?: ALX Oncology saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,120,000 shares, an increase of 7.2% from the March 15th total of 2,910,000 shares. Based on an average daily trading volume, of 389,200 shares, the short-interest ratio is currently 8.0 days. Currently, 11.5% of the company's stock are short sold.
View ALX Oncology's Short Interest.
When is ALX Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ALXO earnings forecast.
How were ALX Oncology's earnings last quarter?: ALX Oncology Holdings Inc. (NASDAQ:ALXO) posted its quarterly earnings results on Thursday, March, 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by $0.09.

What ETF holds ALX Oncology's stock?: Inspire Small/Mid Cap ETF holds 33,156 shares of ALXO stock, representing 0.23% of its portfolio.
What other stocks do shareholders of ALX Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and
When did ALX Oncology IPO?: ALX Oncology (ALXO) raised $128 million in an IPO on Friday, July 17th 2020. The company issued 8,000,000 shares at a price of $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager.
Who are ALX Oncology's major shareholders?: ALX Oncology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.20%). Insiders that own company stock include Jason Lettmann, Jaume Pons, Lsv Associates, Llc, Peter S Garcia, Peter S Garcia, Shelly Pinto and Sophia Randolph.
View institutional ownership trends.
How do I buy shares of ALX Oncology?: Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALXO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ALX Oncology (ALXO) Stock Price, News & Analysis

ALX Oncology MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ALX Oncology Stock (NASDAQ:ALXO)

ALXO Stock Price History

ALXO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ALXO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™